DE69626621D1 - Synthese von n-substituierten oligomeren - Google Patents

Synthese von n-substituierten oligomeren

Info

Publication number
DE69626621D1
DE69626621D1 DE69626621T DE69626621T DE69626621D1 DE 69626621 D1 DE69626621 D1 DE 69626621D1 DE 69626621 T DE69626621 T DE 69626621T DE 69626621 T DE69626621 T DE 69626621T DE 69626621 D1 DE69626621 D1 DE 69626621D1
Authority
DE
Germany
Prior art keywords
compounds
oligomers
substituted
nsgs
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69626621T
Other languages
English (en)
Other versions
DE69626621T2 (de
Inventor
N Zuckermann
A Goff
Simon Ng
Kerry Spear
O Scott
C Sigmund
A Goldsmith
K Marlowe
Yazhong Pei
Lutz Richter
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69626621D1 publication Critical patent/DE69626621D1/de
Application granted granted Critical
Publication of DE69626621T2 publication Critical patent/DE69626621T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00596—Solid-phase processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polyamides (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69626621T 1995-06-07 1996-06-04 Synthese von n-substituierten oligomeren Expired - Lifetime DE69626621T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US487282 1995-06-07
US08/487,282 US5877278A (en) 1992-09-24 1995-06-07 Synthesis of N-substituted oligomers
PCT/US1996/008832 WO1996040202A1 (en) 1995-06-07 1996-06-04 Synthesis of n-substituted oligomers

Publications (2)

Publication Number Publication Date
DE69626621D1 true DE69626621D1 (de) 2003-04-24
DE69626621T2 DE69626621T2 (de) 2004-03-04

Family

ID=23935100

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69626621T Expired - Lifetime DE69626621T2 (de) 1995-06-07 1996-06-04 Synthese von n-substituierten oligomeren

Country Status (8)

Country Link
US (1) US5877278A (de)
EP (1) EP0789577B1 (de)
JP (2) JP3943593B2 (de)
AT (1) ATE234268T1 (de)
AU (1) AU6253496A (de)
CA (1) CA2221517C (de)
DE (1) DE69626621T2 (de)
WO (1) WO1996040202A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034110B2 (en) * 1994-01-05 2006-04-25 Arqule, Inc. Method of identifying chemical compounds having selected properties for a particular application
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
ATE437887T1 (de) 1997-04-28 2009-08-15 Novartis Vaccines & Diagnostic Vorrichtung zur herstellung von oligomeren, insbesondere peptoiden, mit rückführung der reagenzien
ATE421527T1 (de) * 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
HUP0103260A3 (en) * 1998-03-23 2002-03-28 Harvard College Peptidomimetic compounds and process for their synthesis
WO2001004103A1 (en) * 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6452009B1 (en) 1999-08-19 2002-09-17 Lion Bioscience Ag 4-unsubstituted dihydroisoquinolinone derivatives and combinatorial libraries thereof
EP1210121A2 (de) 1999-08-24 2002-06-05 Cellgate Inc. Verbesserung der verabreichung von medikamenten durch und in epitheliale gewebe durch verwendung von oligoarginine-gruppen
US6783929B1 (en) * 1999-11-02 2004-08-31 Chiron Corporation Biological sample component purification and differential display
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
PT1301213T (pt) * 2000-07-21 2017-04-19 Revance Therapeutics Inc Sistemas de transporte biológico de múltiplos componentes
ATE387507T1 (de) * 2000-12-23 2008-03-15 Novartis Vaccines & Diagnostic Screeningverfahren für die oligonukleotidtransfektion
US7030216B2 (en) * 2001-04-06 2006-04-18 Chiron Corporation Peptoids incorporating chemoselective functionalities
FR2825095B1 (fr) * 2001-05-28 2003-09-26 Dev Des Antigenes Combinatoire Dispositif de presentation de polypeptides, utilisable comme "puce" pour la detection miniaturisee de molecules
KR100418962B1 (ko) * 2001-06-07 2004-02-14 김학주 2-(4-나이트로페닐설포닐)에톡시카르보닐-아미노산류를사용하여 펩티드를 고수율 및 고순도로 제조하는 방법
IL150601A (en) * 2001-07-19 2010-06-30 Organon Nv Process for rapid synthesis of peptides within a solution using the back of an activated carboxyl component and destruction of the residual activated carboxyl component
AU2003289386A1 (en) * 2002-12-18 2004-07-09 Takeda Pharmaceutical Company Limited Jnk inhibitors
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
WO2006076687A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US7338775B1 (en) 2005-02-09 2008-03-04 Myriad Genetics, Inc. Enzyme assay and use thereof
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
KR20080048527A (ko) 2005-09-09 2008-06-02 노파르티스 아게 프리온-특이적 펩토이드 시약
US7834038B2 (en) * 2005-11-09 2010-11-16 New York University Methods for preparing nonpeptidic oligomers from amino acids
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
FR2896502B1 (fr) * 2006-01-25 2010-09-24 Scras Nouvelle methode de synthese de 1,4-morpholine-2,5-diones
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
WO2008005479A2 (en) * 2006-07-06 2008-01-10 University Of Wyoming Charge reversible polymers
US20110189692A1 (en) * 2008-04-30 2011-08-04 Novartis Ag Assay for pathogenic conformers
WO2010017412A1 (en) 2008-08-06 2010-02-11 The Regents Of The University Of California Novel biomimetic peptoid polymers
EP2358790B2 (de) 2008-12-16 2016-09-21 Dow Corning Corporation Herstellung von siloxanen
PL2379104T3 (pl) 2008-12-31 2018-07-31 Revance Therapeutics, Inc. Preparaty toksyny botulinowej do wstrzykiwania
WO2010098843A2 (en) 2009-02-24 2010-09-02 New York University Peptoid oligomers, pharmaceutical compositions and methods of using the same
JP6140445B2 (ja) 2009-04-01 2017-05-31 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 血管の過敏反応と関連した皮膚状態を治療する方法および組成物
US20130109581A1 (en) 2009-11-04 2013-05-02 David Peretz Positively charged species as binding reagents in the separation of protein aggregates from monomers
CA2786758A1 (en) 2010-01-14 2011-07-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
WO2012030949A2 (en) 2010-09-01 2012-03-08 Kansas State University Research Foundation B2-glycoprotein i peptide inhibitors
WO2012094163A1 (en) 2011-01-07 2012-07-12 Revance Therapeutics, Inc. Methods and kits for topical application, removal, and inactivation of therapeutic or cosmetic toxin compositions
CA2838793C (en) 2011-07-19 2019-08-06 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
US20140046052A1 (en) 2011-09-21 2014-02-13 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
US9162223B2 (en) * 2011-12-21 2015-10-20 North Carolina State University Alkaline-stable chromatographic resins
AU2013234988A1 (en) 2012-03-22 2014-10-09 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN102850271A (zh) * 2012-09-10 2013-01-02 盛世泰科生物医药技术(苏州)有限公司 3-(1-氨乙基)-2-环丁基-2-氢-异喹啉-1-酮类化合物的合成
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3578184A1 (de) 2013-03-12 2019-12-11 Baxalta GmbH Resorptionsförderer als additive zur verbesserung der oralen formulierung von niedermolekularen heparinen
IL229134A0 (en) 2013-10-29 2014-03-31 Omrix Biopharmaceuticals Ltd Compounds and methods for stabilizing thrombin activity
BR112016009954A2 (pt) 2013-11-04 2017-12-05 Univ California terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação
IL230151A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing a polymerization inhibitor
IL231792A0 (en) 2014-03-27 2014-08-31 Omrix Biopharmaceuticals Ltd Device and method for the preparation and administration of one-component fibrin glue
CN107109701B (zh) * 2014-09-16 2020-10-09 斯坦福国际研究院 通过光纤阵列扫描技术发现亲和试剂和催化剂
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN108347916B (zh) 2015-10-14 2022-02-08 先时迈纳米生物科技股份有限公司 一种减少冰晶形成的组合物及其方法
SG11201803566TA (en) 2015-10-29 2018-05-30 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
EP3426673B1 (de) * 2016-03-09 2021-05-05 Mike-Ann, LLC Peptoidaffinitätsliganden
EP3500590A4 (de) 2016-08-18 2020-04-29 The Board of Trustees of the Leland Stanford Junior University Herstellung und verwendung von phosphoethanolamincellulose und derivaten
WO2018075822A1 (en) 2016-10-19 2018-04-26 Avive, Inc. Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
US11795579B2 (en) 2017-12-11 2023-10-24 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
WO2020257586A2 (en) 2019-06-20 2020-12-24 Baxalta Incorporated Method of treatment with viral-based gene therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634364A (en) * 1969-09-26 1972-01-11 Grace W R & Co Polyminodiacetic acid and polysarcosine homopolymers
DE2447305C3 (de) * 1973-10-05 1979-09-13 Miyoshi Yushi K.K., Tokio Verfahren zur Herstellung chelatbildender Polymerisate
WO1986000991A1 (en) * 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5225533A (en) * 1988-05-02 1993-07-06 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5252296A (en) * 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP1258492A1 (de) * 1992-09-24 2002-11-20 Chiron Corporation N-substituierte Oligomere und Verfahren zu deren Synthese, z.B. Polyglycin gebundene Nukleinsäurebasen
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
DE19910988A1 (de) * 1999-03-11 2000-09-14 Bosch Gmbh Robert Elektronisches Gerät, insbesondere Fernmeldevermittlungsanlage

Also Published As

Publication number Publication date
CA2221517C (en) 2008-11-18
ATE234268T1 (de) 2003-03-15
CA2221517A1 (en) 1996-12-19
JP3943593B2 (ja) 2007-07-11
AU6253496A (en) 1996-12-30
EP0789577A1 (de) 1997-08-20
US5877278A (en) 1999-03-02
DE69626621T2 (de) 2004-03-04
JP2006182780A (ja) 2006-07-13
WO1996040202A1 (en) 1996-12-19
EP0789577B1 (de) 2003-03-12
JPH11507049A (ja) 1999-06-22
EP0789577A4 (de) 1998-07-22

Similar Documents

Publication Publication Date Title
DE69626621D1 (de) Synthese von n-substituierten oligomeren
NO950682L (no) Syntese av N-substituerte oligomerer
Burbaum et al. A paradigm for drug discovery employing encoded combinatorial libraries.
Frenkel-Pinter et al. Selective incorporation of proteinaceous over nonproteinaceous cationic amino acids in model prebiotic oligomerization reactions
Houghten et al. Mixture-based synthetic combinatorial libraries
Biron et al. Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis
Lam et al. The “one-bead-one-compound” combinatorial library method
US5891737A (en) Combinatorial non-peptide libraries
US5646285A (en) Combinatorial non-peptide libraries
CA2424611A1 (en) Identification of protein binding sites
ATE176239T1 (de) Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
Huc et al. Dynamic combinatorial chemistry
ATE203025T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
JPH06504758A (ja) プロテアーゼ耐性を有する修飾ペプチドのライブラリー
Davies et al. Screening an inverted peptide library in water with a guanidinium-based tweezer receptor
ATE346857T1 (de) Kombinatorische herstellung von bibliotheken aus makrozyklischen verbindungen zur entdeckung von pharmazeutischen wirkstoffen
WO2005040073A3 (en) Solid phase synthesis of 3-aryl-2- indolylcarboxylic acids
Blondelle et al. Soluble combinatorial libraries of organic, peptidomimetic and peptide diversities
PT1107981E (pt) Sintese de analogos peptidicos ciclicos de anel modificado
EP0804460A1 (de) Konformationsbeschränkte bibliothek mit umgekehrter diehung und dazu beziehende verfahren
Eichler et al. Generation and utilization of synthetic combinatorial libraries
Bleczinski et al. Solid-Phase Synthesis of Cyclic Peptide− DNA Hybrids
ATE509912T1 (de) Oligomere und polymere von zyklischen imino- carbonsäuren
Simon et al. Using peptoid libraries [oligo N-substituted glycines] for drug discovery
Cho et al. Cyclic and linear oligocarbamate ligands for human thrombin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US